However, since type 2, and not type 1, is a nuclear form (Takao et al., 1999; Ohtsubo et al., 2000), and somatic APC mutations occur in the nuclear DNA of MAP tumors (Al-Tassan et al., 2002), we think that evaluation of type 2 variants is likely to be more preferable when we investigate the possible pathogenic role of MUTYH in MAP. This evidence concerns the gene APC and mutyh-associated polyposis.